News
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
ENGLEWOOD, CO / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today...
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte’s Technology Fast 500™ for Second Year in a Row
Ranked 94th Fastest Growing Company in North AmericaRanked 21st Fastest Growing Life Sciences CompanyENGLEWOOD, CO / November 17, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing...
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
ENGLEWOOD, CO / November 16, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the...
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx SegmentPositive Adjusted EBITDA for the Quarter of $1.4 MillionLeadership Changes Implemented to Focus on Commercial OperationsCompany to Host Conference Call Today at 4:30pm ETENGLEWOOD, CO /...
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
ENGLEWOOD, CO / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company’s Term Loan
Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024Amendment Defers Over $3 Million in Principal Payments Beyond 2023Note Matures in January 2025, with Additional Extensions of the Interest-Only Period Available, Subject to Achievement of...
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin, Healight, and NT0502, and focusing on revenue growth and near-term cash flow generationAytu is expecting to generate...
Aytu BioPharma (AYTU) Fireside Chat
In this presentation, we welcome Aytu BioPharma, NASDAQ ticker symbol of AYTU. And with us today is their Chief Executive Officer, Josh Disbrow. Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. This...
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
ENGLEWOOD, CO / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth...
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndrome (VEDS).Multiple Patent Families Filed in Key Global...